Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Jan;84(1):71–80.

Pharmacological effects of (+/-)-11-deoxy, 16-phenoxy-prostaglandin E1 derivatives in the cardiovascular system.

A K Banerjee, D P Tuffin, J L Walker
PMCID: PMC1987233  PMID: 3884073

Abstract

M&B 28,767 [(+/-)-11-deoxy-16-phenoxy-17,18,19,20-tetranor prostaglandin E1] and a series of close analogues have been compared with U-46619 [(15S)-hydroxy-11 alpha, 9 alpha-(epoxymethano)-prosta-(5Z,13E)-dienoic acid] for prostaglandin endoperoxide-like pharmacological actions in vitro and in vivo. M&B 28,767 caused powerful dose-related contraction of rabbit aorta (EC50: 2.0 microM) and mesenteric artery (EC50: 0.2 microM) strips in vitro, but was less active than U-46619 and/or noradrenaline. M&B 28,767 induced rapid and irreversible aggregation of rat (0.9 times potency of U-46619) and human (0.25 times potency of U-46619) platelets in platelet-rich plasma (PRP) in vitro. Intravenous administration of M&B 28,767 to urethane-allobarbitone anaesthetized rats produced immediate and dose-related thrombocytopoenia (equipotent with U-46619), accompanied in some animals by transient small pressor effects at low doses (1-2 micrograms kg-1) which were not statistically significant and invariably by sharp depressor effects at higher doses (3-10 micrograms kg-1). U-46619 caused moderate, but not dose-related, pressor effects at all doses tested. Considerable variation in potency occurred amongst the thirteen structural analogues of M&B 28,767. Platelet aggregatory activity for those members of the 11-deoxy 16-phenoxy-PGE1 series tested in rat PRP in vitro demonstrated a positive and significant correlation with pro-aggregatory activity in vivo and agonist potency on rabbit aortic strip in vitro.

Full text

PDF
76

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong R. A., Jones R. L., Wilson N. H. Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br J Pharmacol. 1983 Aug;79(4):953–964. doi: 10.1111/j.1476-5381.1983.tb10541.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Banerjee A. K., Broughton B. J., Burton T. S., Caton M. P., Christmas A. J., Coffee E. C., Crowshaw K., Hardy C. J., Heazell M. A., Palfreyman M. N. Synthesis and anti-ulcer activity of 16-phenoxy analogues of (+)-11-deoxyprostaglandin E1. Prostaglandins. 1981 Aug;22(2):167–182. doi: 10.1016/0090-6980(81)90032-0. [DOI] [PubMed] [Google Scholar]
  3. Banerjee A. K., Broughton B. J., Burton T. S., Caton M. P., Christmas A. J., Coffee E. C., Crowshaw K., Heazell M. A., Stuttle K. A., Watkins G. L. Synthesis and gastrointestinal pharmacology of some 15- and 16- modified (+/-)-11-deoxyprostaglandins. Prostaglandins. 1978 Oct;16(4):541–554. doi: 10.1016/0090-6980(78)90184-3. [DOI] [PubMed] [Google Scholar]
  4. Best L. C., McGuire M. B., Martin T. J., Preston F. E., Russell R. G. Effects of epoxymethano analogues of prostaglandin endoperoxides on aggregation, on release of 5-hydroxytryptamine and on the metabolism of 3',5'-cyclic AMP and cyclic GMP in human platelets. Biochim Biophys Acta. 1979 Mar 22;583(3):344–351. doi: 10.1016/0304-4165(79)90458-6. [DOI] [PubMed] [Google Scholar]
  5. Broughton B. J., Caton M. P., Coffee E. C., Hambling D. J., Palfreyman M. N., Withnall M. T., Wooldridge K. R. Synthesis and antifertility activity of omega-chain phenyl- and 16-phenoxy-analogues of (+/-)-11-deoxyprostaglandin F1 alpha. Prostaglandins. 1980 Apr;19(4):559–575. doi: 10.1016/s0090-6980(80)80006-2. [DOI] [PubMed] [Google Scholar]
  6. Coleman R. A., Humphrey P. P., Kennedy I., Levy G. P., Lumley P. Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol. 1981 Jul;73(3):773–778. doi: 10.1111/j.1476-5381.1981.tb16814.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Coleman R. A., Humphrey P. P., Kennedy I., Levy G. P., Lumley P. U-46619, a selective thromboxane A2-like agonist? [proceedings]. Br J Pharmacol. 1980 Jan;68(1):127P–128P. [PMC free article] [PubMed] [Google Scholar]
  8. Crossley N. S. The synthesis and biological activity of potent, selective luteolytic prostaglandins. Prostaglandins. 1975 Jul;10(1):5–18. doi: 10.1016/0090-6980(75)90090-8. [DOI] [PubMed] [Google Scholar]
  9. Dukes M., Russell W., Walpole A. L. Potent luteolytic agents related to prostaglandin F2alpha. Nature. 1974 Jul 26;250(464):330–331. doi: 10.1038/250330a0. [DOI] [PubMed] [Google Scholar]
  10. Fitzpatrick F. A., Bundy G. L., Gorman R. R., Honohan T. 9,11-epoxyiminoprosta-5,13-dienoic acid is a thromboxane A2 antagonist in human platelets. Nature. 1978 Oct 26;275(5682):764–766. doi: 10.1038/275764a0. [DOI] [PubMed] [Google Scholar]
  11. Jones R. L., Marr C. G. Actions of 16-aryloxy analogues of prostaglandin F2alpha on preparations responsive to prostaglandin endoperoxides. Br J Pharmacol. 1977 Dec;61(4):694–696. doi: 10.1111/j.1476-5381.1977.tb07563.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jones R. L., Wilson N. H. A 16-p-fluorophenoxy prostanoid with potent and long-lasting thromboxane-like actions [proceedings]. Br J Pharmacol. 1978 Jun;63(2):362P–362P. [PMC free article] [PubMed] [Google Scholar]
  13. MacIntyre D. E., Westwick J., Williams T. J. Comparison of the effects of prostaglandin analogues on rabbit platelets, rabbit isolated vascular tissues and rabbit skin microvasculature [proceedings]. Br J Pharmacol. 1978 Mar;62(3):418P–420P. [PMC free article] [PubMed] [Google Scholar]
  14. Malmsten C. Some biological effects of prostaglandin endoperoxide analogs. Life Sci. 1976 Jan 15;18(2):169–176. doi: 10.1016/0024-3205(76)90021-7. [DOI] [PubMed] [Google Scholar]
  15. Smith G. M., Duncan G. G. A study of intravascular platelet aggregation by continuous platelet counting. Thromb Res. 1981 Aug 1;23(3):275–288. doi: 10.1016/0049-3848(81)90017-7. [DOI] [PubMed] [Google Scholar]
  16. Smith G. M., Freuler F. The measurement of intravascular aggregation by continuous platelet counting. Bibl Anat. 1973;12:229–234. [PubMed] [Google Scholar]
  17. VANE J. R. THE USE OF ISOLATED ORGANS FOR DETECTING ACTIVE SUBSTANCES IN THE CIRCULATING BLOOD. Br J Pharmacol Chemother. 1964 Oct;23:360–373. doi: 10.1111/j.1476-5381.1964.tb01592.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. di Minno G., Bertelé V., Bianchi L., Barbieri B., Cerletti C., Dejana E., de Gaetano G., Silver M. J. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets. Thromb Haemost. 1981 Apr 30;45(2):103–106. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES